Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China
Abstract Combination antiretroviral therapy (ART) has improved outcomes for human immunodeficiency virus (HIV) associated non-Hodgkin lymphoma. This is an analysis of 127 patients with HIV with Burkitt lymphoma (HIV-BL) and diffuse large B-cell lymphoma (HIV-DLBCL) treated at the Zhongnan Hospital o...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-80749-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850137132120670208 |
|---|---|
| author | Yu Xiong Weicheng Liu Xiaoping Chen Pingzheng Mo Yong Xiong Liping Deng Yongxi Zhang |
| author_facet | Yu Xiong Weicheng Liu Xiaoping Chen Pingzheng Mo Yong Xiong Liping Deng Yongxi Zhang |
| author_sort | Yu Xiong |
| collection | DOAJ |
| description | Abstract Combination antiretroviral therapy (ART) has improved outcomes for human immunodeficiency virus (HIV) associated non-Hodgkin lymphoma. This is an analysis of 127 patients with HIV with Burkitt lymphoma (HIV-BL) and diffuse large B-cell lymphoma (HIV-DLBCL) treated at the Zhongnan Hospital of Wuhan University over a 17-year period during the ART and rituximab era. The median CD4 count for the cohorts was 0.141 × 109/L (range, 0.001-0.861 × 109/L). DA-EPOCH ± R (54%) were most commonly used in HIV-BL. CHOP± R (42%) was most commonly used to treat HIV-DLBCL. The complete response rate after first-line curative therapy was 10/28 (36%) in HIV-BL and 25/57 (44%) in HIV-DLBCL. The 2-year progression-free survival (PFS) and overall survival (OS) for the HIV-BL cohort was 50% and 41% respectively. The 2-year PFS and OS for the HIV-DLBCL cohort was 55% and 47% respectively. Current China practice favours the treatment of HIV-BL and HIV-DLBCL similarly to the HIV-negative population with the use of concurrent ART. However, due to the extremely low percentage of patients receiving ART prior to the lymphoma diagnosis, the high percentage of patients with poor performance status, and the advanced stage at diagnosis, the treatment of HIV-related lymphoma remains the major challenge in China. |
| format | Article |
| id | doaj-art-2f048e5441c0489fbbb4b4d56e248dca |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-2f048e5441c0489fbbb4b4d56e248dca2025-08-20T02:30:56ZengNature PortfolioScientific Reports2045-23222024-12-011411910.1038/s41598-024-80749-9Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in ChinaYu Xiong0Weicheng Liu1Xiaoping Chen2Pingzheng Mo3Yong Xiong4Liping Deng5Yongxi Zhang6Department of Radiation and Medical Oncology for Esophageal Mediastinal and Lymphatic Tumors, Zhongnan Hospital of Wuhan UniversityDepartment of Colorectal and Anal Surgery (Clinical Center for Pelvic Floor Surgery), Zhongnan Hospital of Wuhan UniversityDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan UniversityDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan UniversityDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan UniversityDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan UniversityDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan UniversityAbstract Combination antiretroviral therapy (ART) has improved outcomes for human immunodeficiency virus (HIV) associated non-Hodgkin lymphoma. This is an analysis of 127 patients with HIV with Burkitt lymphoma (HIV-BL) and diffuse large B-cell lymphoma (HIV-DLBCL) treated at the Zhongnan Hospital of Wuhan University over a 17-year period during the ART and rituximab era. The median CD4 count for the cohorts was 0.141 × 109/L (range, 0.001-0.861 × 109/L). DA-EPOCH ± R (54%) were most commonly used in HIV-BL. CHOP± R (42%) was most commonly used to treat HIV-DLBCL. The complete response rate after first-line curative therapy was 10/28 (36%) in HIV-BL and 25/57 (44%) in HIV-DLBCL. The 2-year progression-free survival (PFS) and overall survival (OS) for the HIV-BL cohort was 50% and 41% respectively. The 2-year PFS and OS for the HIV-DLBCL cohort was 55% and 47% respectively. Current China practice favours the treatment of HIV-BL and HIV-DLBCL similarly to the HIV-negative population with the use of concurrent ART. However, due to the extremely low percentage of patients receiving ART prior to the lymphoma diagnosis, the high percentage of patients with poor performance status, and the advanced stage at diagnosis, the treatment of HIV-related lymphoma remains the major challenge in China.https://doi.org/10.1038/s41598-024-80749-9 |
| spellingShingle | Yu Xiong Weicheng Liu Xiaoping Chen Pingzheng Mo Yong Xiong Liping Deng Yongxi Zhang Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China Scientific Reports |
| title | Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China |
| title_full | Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China |
| title_fullStr | Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China |
| title_full_unstemmed | Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China |
| title_short | Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China |
| title_sort | survival of hiv associated diffuse large b cell lymphoma and burkitt lymphoma in china |
| url | https://doi.org/10.1038/s41598-024-80749-9 |
| work_keys_str_mv | AT yuxiong survivalofhivassociateddiffuselargebcelllymphomaandburkittlymphomainchina AT weichengliu survivalofhivassociateddiffuselargebcelllymphomaandburkittlymphomainchina AT xiaopingchen survivalofhivassociateddiffuselargebcelllymphomaandburkittlymphomainchina AT pingzhengmo survivalofhivassociateddiffuselargebcelllymphomaandburkittlymphomainchina AT yongxiong survivalofhivassociateddiffuselargebcelllymphomaandburkittlymphomainchina AT lipingdeng survivalofhivassociateddiffuselargebcelllymphomaandburkittlymphomainchina AT yongxizhang survivalofhivassociateddiffuselargebcelllymphomaandburkittlymphomainchina |